GUBR.F Stock Overview
A biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Gubra A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 60.15 |
| 52 Week High | DKK 102.41 |
| 52 Week Low | DKK 60.15 |
| Beta | 0.51 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -35.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| GUBR.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | n/a | 0.7% | 2.2% |
| 1Y | n/a | -26.6% | 8.2% |
Return vs Industry: Insufficient data to determine how GUBR.F performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how GUBR.F performed against the US Market.
Price Volatility
| GUBR.F volatility | |
|---|---|
| GUBR.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 10.9% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: GUBR.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine GUBR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 260 | Henrik Blou | www.gubra.dk |
Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, pharmacokinetics, and 2D and 3D histology with artificial intelligence pathology.
Gubra A/S Fundamentals Summary
| GUBR.F fundamental statistics | |
|---|---|
| Market cap | US$971.88m |
| Earnings (TTM) | -US$5.56m |
| Revenue (TTM) | US$40.51m |
24.0x
P/S Ratio-174.7x
P/E RatioIs GUBR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GUBR.F income statement (TTM) | |
|---|---|
| Revenue | DKK 265.74m |
| Cost of Revenue | DKK 101.24m |
| Gross Profit | DKK 164.50m |
| Other Expenses | DKK 201.00m |
| Earnings | -DKK 36.50m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Aug 21, 2025
| Earnings per share (EPS) | -2.24 |
| Gross Margin | 61.90% |
| Net Profit Margin | -13.73% |
| Debt/Equity Ratio | 0% |
How did GUBR.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 00:59 |
| End of Day Share Price | 2025/05/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gubra A/S is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rune Dahl | DNB Markets |